Conflicting verdicts on peanut oral immunotherapy from the Institute for Clinical and Economic Review and US Food and Drug Administration Advisory Committee: Where do we go from here?
ContributorsEiwegger, Thomas; Anagnostou, Katherine; Arasi, Stefania; Bégin, Philippe; Ben-Shoshan, Moshe; Beyer, Kirsten; Blumchen, Katharina; Brough, Helen; Caubet, Jean-Christoph Roger J-P; Chan, Edmond S; Chen, Meng; Chinthrajah, Sharon; Davis, Carla M; Des Roches, Anne; Du Toit, George; Elizur, Arnon; Galli, Stephen J; Håland, Geir; Hoffmann-Sommergruber, Karin; Kim, Harold; Leung, Donald Y M; Long, Andrew; Muraro, Antonella; Nurmatov, Ulugbek B; Pajno, Giovanni B; Sampath, Vanitha; Saxena, Jamie; Sindher, Sayantani; Upton, Julia; Worm, Margitta; Nadeau, Kari C
Published inJournal of Allergy and Clinical Immunology, vol. 145, no. 4, p. 1153-1156
Publication date2020
Keywords
- Food allergy
- Institute for Clinical and Economic Review
- US Food and Drug Administration Allergenic Products Advisory Committee
- Efficacy
- Management
- Peanut allergy
- Quality of life
- Safety
- Treatment
Affiliation entities
Research groups
Citation (ISO format)
EIWEGGER, Thomas et al. Conflicting verdicts on peanut oral immunotherapy from the Institute for Clinical and Economic Review and US Food and Drug Administration Advisory Committee: Where do we go from here? In: Journal of Allergy and Clinical Immunology, 2020, vol. 145, n° 4, p. 1153–1156. doi: 10.1016/j.jaci.2019.10.021
Main files (1)
Article (Published version)
Identifiers
- PID : unige:151787
- DOI : 10.1016/j.jaci.2019.10.021
- PMID : 31678426
Journal ISSN0091-6749
